“Orange Book” Patent Listing Declarations Need More Detail – GPhA
Executive Summary
FDA should require more detailed patent declarations for listing in the "Orange Book," a Generic Pharmaceutical Association proposal states
You may also be interested in...
GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns
The generic industry should consider carefully any attempt to derail FDA's regulatory approach to Waxman/Hatch reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association
GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns
The generic industry should consider carefully any attempt to derail FDA's regulatory approach to Waxman/Hatch reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association
FDA Waxman/Hatch Fix Proposal Is “Beefed-Up” Patent Declarations
FDA is considering requiring innovator companies to provide more information about patents they file for listing in the "Orange Book" as one remedy to Waxman/Hatch loopholes